Outcomes when stage IV non-small cell lung cancer (NSCLC4) patients (pts) harboring oncogenic drivers (OD) are treated initially without tyrosine kinase inhibitors (TKI) Meeting Abstract (Web of Science)

cited authors

  • Choksi, R.; Smith, R.; Johnson, M.; Gordan, L.; Xue, M.; Varughese, P.; Dorrow, N.; Wang, B.; Vaidya, V.; Vasudevan, A.; Gart, M.; Gierman, H.; Scott, J.

publication date

  • September 1, 2022

webpage

published in

category

start page

  • S1057

end page

  • S1058

volume

  • 33

issue

  • 7